Amgen CEO Bradway Buys 120K Shares at $156—Below Market, Signaling Confidence in Biotech Pipeline

Insider Activity at Amgen: A Close‑Read of Bradway’s Recent Deal

Amgen’s latest Form 4 filing shows Chairman, CEO and President Bradway Robert A acquiring 119,782 shares of the company’s common stock on March 4, 2026. The purchase was executed at a price of $156.35 per share—well below the market price of $369.51—reflecting a non‑market exercise of stock options that were vested in early May. By buying the shares, Bradway increased his post‑transaction holdings to 576,928 shares, representing roughly 0.28 % of the outstanding equity. The transaction aligns with Amgen’s broader insider activity, where several executives made sizable purchases in the same week, suggesting confidence in the company’s near‑term prospects.

What the Deal Means for Investors

A buy at a deep discount can signal management’s belief that the stock is undervalued, especially given Amgen’s recent dividend declaration for Q2 2026 and the upcoming shareholder meeting. Investors often interpret such insider purchases as a bullish endorsement; however, the 13‑point negative sentiment on social media and the 76 % buzz indicate that the market reaction is muted, perhaps due to the company’s modest weekly decline of –4.81 %. For long‑term holders, Bradway’s action may reinforce the narrative that Amgen’s biotech pipeline, supported by its robust market cap of $204 B and a P/E of 25.2, remains solid. Short‑term traders should note that the purchase, while sizable, is a small fraction of the total shares outstanding, and its impact on the stock price is likely limited.

Bradway Robert A: A Transaction Profile

Bradway’s insider trading history reveals a pattern of disciplined, incremental buying. Over the past 18 months, he has made four significant purchases of common stock, each accompanied by a simultaneous acquisition of right‑to‑buy (Nqso) options that are exercised at later dates. In May 2025, he bought 13,311 shares and 86,042 Nqsos; in March 2026, he purchased 42,657 shares. His holdings have hovered around 90,000 shares in the past, indicating a long‑term commitment to the company. Unlike other executives who have sold shares (e.g., Santos Esteban’s recent sell of 30,501 shares), Bradway’s consistent buying pattern suggests confidence in Amgen’s strategic direction, particularly its focus on novel therapeutics and upcoming product launches.

Implications for Amgen’s Future

The confluence of insider buying, a declared dividend, and a scheduled conference appearance by CFO Peter Griffith points to a period of shareholder value creation for Amgen. Bradway’s purchase adds credibility to the company’s earnings guidance and may encourage other investors to view the stock as a defensive play in a volatile healthcare sector. While the stock’s 52‑week high is still above the current price, the recent downward trend and high market cap position Amgen as a stable, albeit mature, player in biotechnology. Investors looking for exposure to established biopharma should weigh the potential for dividend income against the company’s modest upside potential, given its current valuation metrics.